Literature DB >> 36219278

Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen: Comparison of Surveillance Strategies Among Patients Who Underwent Resection of Colorectal Cancer-A Systematic Review and Meta-analysis.

Zaiba Shafik Dawood1, Laura Alaimo2, Henrique A Lima2, Zorays Moazzam2, Chanza Shaikh2, Ahmed Sayed Ahmed3, Muhammad Musaab Munir2, Yutaka Endo2, Timothy M Pawlik4.   

Abstract

BACKGROUND: Almost one-third of colorectal cancer (CRC) patients experience recurrence after resection; nevertheless, follow-up strategies remain controversial. We sought to systematically assess and compare the accuracy of carcinoembryonic antigen (CEA), imaging [positron emission tomography (PET) and computed tomography (CT) scans], and circulating tumor DNA (CtDNA) as surveillance strategies. PATIENTS AND METHODS: PubMed, Medline, Embase, Scopus, Cochrane, Web of Science, and CINAHL were systematically searched. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was used to assess methodological quality. We performed a bivariate random-effects meta-analysis and reported pooled sensitivity, specificity, and diagnostic odds ratio (DOR) values for each surveillance strategy.
RESULTS: Thirty studies were included in the analysis. PET scans had the highest sensitivity to detect recurrence (0.95; 95%CI 0.91-0.97), followed by CT scans (0.77; 95%CI 0.67-0.85). CtDNA positivity had the highest specificity to detect recurrence (0.95; 95%CI 0.91-0.97), followed by increased CEA levels (0.88; 95%CI 0.82-0.92). Furthermore, PET scans had the highest DOR to detect recurrence (DOR 120.7; 95%CI 48.9-297.9) followed by CtDNA (DOR 37.6; 95%CI 20.8-68.0).
CONCLUSION: PET scans had the highest sensitivity and DOR to detect recurrence, while CtDNA had the highest specificity and second highest DOR. Combinations of traditional cross-sectional/functional imaging and newer platforms such as CtDNA may result in optimized surveillance of patients following resection of CRC.
© 2022. Society of Surgical Oncology.

Entities:  

Year:  2022        PMID: 36219278     DOI: 10.1245/s10434-022-12641-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  62 in total

Review 1.  Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.

Authors:  Robert P Jones; Siân A Pugh; Janet Graham; John N Primrose; Jorge Barriuso
Journal:  Eur J Cancer       Date:  2021-01-07       Impact factor: 9.162

2.  Cost-effectiveness analysis of postoperative surveillance protocols following radical surgery for colorectal cancer.

Authors:  L Di Cristofaro; M Scarpa; I Angriman; E Perissinotto; C Ruffolo; M Frego; F Erroi
Journal:  Acta Chir Belg       Date:  2012-01       Impact factor: 1.090

3.  The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer.

Authors:  Jon D Vogel; Seth I Felder; Anuradha R Bhama; Alexander T Hawkins; Sean J Langenfeld; Virginia O Shaffer; Amy J Thorsen; Martin R Weiser; George J Chang; Amy L Lightner; Daniel L Feingold; Ian M Paquette
Journal:  Dis Colon Rectum       Date:  2022-02-01       Impact factor: 4.585

4.  The role of postoperative surveillance in colorectal cancer.

Authors:  Kerry Hammond; David A Margolin
Journal:  Clin Colon Rectal Surg       Date:  2007-08

5.  Reoperation for recurrent colorectal cancer.

Authors:  Michael D Hellinger; Cesar A Santiago
Journal:  Clin Colon Rectal Surg       Date:  2006-11

Review 6.  Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer.

Authors:  Emile Tan; Nikos Gouvas; R John Nicholls; Paul Ziprin; Evaghelos Xynos; Paris P Tekkis
Journal:  Surg Oncol       Date:  2008-07-10       Impact factor: 3.279

7.  The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.

Authors:  Rachel Wong; Jeanne Tie; Margaret Lee; Joshua Cohen; Yuxuan Wang; Lu Li; Stephen Ma; Michael Christie; Suzanne Kosmider; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal:  Int J Cancer       Date:  2019-01-24       Impact factor: 7.396

8.  Early Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer.

Authors:  Benjamin A Weinberg; Emily R Winslow; Mohammed Bayasi; Michael R Krainock; Perry M Olshan; Paul R Billings; Alexey Aleshin
Journal:  Case Rep Oncol       Date:  2021-12-10

9.  Evaluation of CEA in patients with known residual disease after resection of colonic cancer.

Authors:  J O Lawton; G R Giles; E H Cooper
Journal:  J R Soc Med       Date:  1980-01       Impact factor: 18.000

10.  Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.

Authors:  Alexander R Siebenhüner; Ulrich Güller; Rene Warschkow
Journal:  BMC Cancer       Date:  2020-03-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.